LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc., a publicly held biotechnology company, today announced positive Phase I data on the Company’s prostate cancer drug CB7630 (abiraterone acetate). The data was presented today during the plenary session at the National Cancer Research Institute (NCRI) Cancer Conference that is currently taking place October 8-11, 2006 in Birmingham, UK. The presentation, entitled “Inhibition of androgen synthesis by an oral, irreversible, inhibitor of CYP450c17 appears safe and results in a high, durable, response rate in castration refractory prostate cancer (CRPC) patients,” was made by Dr. Johann S. deBono, MSc, PhD, MD, FRCP from the Institute of Cancer Research and Royal Marsden Hospital in Sutton, UK.
